Harrow Health, Inc. (HROW)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Harrow Health, Inc. (HROW) is down 13.5% since the beginning of the year. At $42 per share, HROW is trading 22.7% below its 52-week high of $55. Investors who bought $1,000 worth of HROW shares 5 years ago would now be looking at an investment worth $4,296.

Harrow Health, Inc. (HROW) has returned -13.45% so far this year and 38.32% over the past 12 months. Looking at the last ten years, HROW has achieved an annualized return of 26.69%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Sep 28, 2007, HROW's average daily return is +0.36%, while the average monthly return is +3.03%. At this rate, an investment would double in approximately 1.9 years.

Historically, 46% of months were positive and 54% were negative. The best month was Nov 2011 with a return of +214.3%, while the worst month was Jun 2011 at -75.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 11 months.

On a daily basis, HROW closed higher 39% of trading days. The best single day was Mar 16, 2012 with a return of +158.9%, while the worst single day was Mar 19, 2012 at -89.7%.

Harrow Health, Inc. has an annualized alpha of 131.66%, beta of 0.52, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 28, 2007.

• This stock participated in 84.99% of S&P 500 Index downside but only 28.94% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.52 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HROW ranks 61 for risk / return — better than 61% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Harrow Health, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Harrow Health, Inc. was 99.46%, occurring on Mar 19, 2012. The portfolio has not yet recovered.

The current Harrow Health, Inc. drawdown is 69.27%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Harrow Health, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Harrow Health, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.